偏头痛中的淋巴系统
发现类淋巴系统在偏头痛发作中的功能作用
This study aimed to investigate the role of the glymphatic system in the initiation of migraine attacks, using non-invasive magnetic resonance imaging techniques and a validated model of migraine induction by nitroglycerin administration. Secondarily, the relationship between the function of the glymphatic system during nitroglycerin-induced migraine attacks and sleep architecture and plasma levels of migraine-involved neuropeptides will be investigated.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Roberta Messina, MD, PhD
- 电话号码:00390226433944
- 邮箱:messina.roberta@hsr.it
学习地点
-
-
Milan
-
Milan、Milan、意大利、20132
- 招聘中
- IRCCS San Raffaele Hospital
-
接触:
- Roberta Messina, MD, PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with a diagnosis of episodic migraine without aura, by the standard ICHD diagnostic criteria, will be prospectively recruited. Patients will be allowed to take only one migraine preventive treatment at a stable dose during the study. Healthy controls suffering from any headaches with the exception of infrequent tension-type headache will be excluded from the study.
描述
Inclusion Criteria:
For patients:
• Diagnosis of migraine, by the ICHD-3 criteria;
For both patients and healthy controls:
- Age between 18 and 60 years;
- Willing and able to comply with scheduled visits.
Exclusion criteria
For patients:
- Overuse of acute medications for headache;
- Continuous or daily headache;
- Other primary headache disorders, with the exception of infrequent tension-type headache.
For healthy controls:
• Any subject with frequent tension type headache, migraine, cluster headache, other pain syndromes or neurological conditions.
For both patients and healthy controls:
- Allergy to nitroglycerin;
- Major psychiatric disorders such as bipolar affective disorder and schizophrenia;
- Cardiovascular diseases that contraindicated the use of nitroglycerin;
- Intracranial hypertension;
- Cerebral haemorrhage;
- Cerebral trauma;
- Pulmonary toxic oedema;
- Closed angle glaucoma;
- Anaemia;
- Pregnancy and breastfeeding;
- Aortic stenosis or significant hypotension (SBP<90mmHg or <100mmHg and symptomatic) precluding nitroglycerin administration;
- Use of sildenafil;
- Any person unable to lie still within the environment of the MRI scanner for the required period to perform the study;
- Any person where MRI scanning is contraindicated (metal implants, pacemaker, claustrophobia, etc.);
- Use of illicit drugs;
- MRI head showing any brain pathology, such as space-occupying lesions;
- Any person unable to understand and follow the instructions of the investigators.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Adult patients with migraine
Diagnosis of migraine, by the ICHD-3 criteria. Age between 18 and 60 years. Female and males. Right-handed |
Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls. The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images. Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis. Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging. |
|
Healthy controls
Age between 18 and 60 years. Female and males. Right-handed |
Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls. The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images. Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis. Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline glymphatic function after nitroglycerin administration
大体时间:Up to 8 hours
|
The DTI-ALPS index will be quantified before and after nitroglycerin administration as an indirect measure of the glymphatic function |
Up to 8 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline plasma levels of neuropeptides after nitroglycerin administration
大体时间:Up to 8 hours
|
ELISA kits will be used to measure the plasma level of neuropeptides involved in migraine pathophysiology before and after nitroglycerin administration |
Up to 8 hours
|
|
Change from baseline sleep architecture after nitroglycerin administration
大体时间:Up to 8 hours
|
Sleep Architecture will be studied through the Sleep Profiler before and after nitroglycerin administration |
Up to 8 hours
|
合作者和调查者
调查人员
- 首席研究员:Roberta Messina, MD, PhD、IRCCS San Raffaele Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.